M Reni
Overview
Explore the profile of M Reni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reni M, Milella M, Bergamo F, Di Marco M, Giommoni E, Cardellino G, et al.
ESMO Open
. 2025 Jan;
10(1):104001.
PMID: 39754983
Background: Non-metastatic pancreatic ductal adenocarcinoma (PDAC) presents a challenging scenario: the rarity of the disease, the limited number of completed prospective trials, and the shortcomings of comparability across series produce...
2.
Reni M, Giommoni E, Bergamo F, Cavanna L, Simionato F, Spada M, et al.
Pancreatology
. 2024 Oct;
24(7):1160-1166.
PMID: 39389862
This analysis from the GARIBALDI study was aimed to address the role of center self-declared expertise, type and commitment on the overall survival (OS) of patients with metastatic Pancreatic Ductal...
3.
Losa M, Mazza E, Pedone E, Nocera G, Liscia N, Reni M, et al.
J Endocrinol Invest
. 2024 May;
47(11):2835-2842.
PMID: 38696125
Background: Papillary craniopharyngiomas harbor the BRAF V600E mutation, which paves the way for using BRAF inhibitor molecules to treat tumors refractory to standard therapies. Single case reports confirmed the efficacy...
4.
Reni M, Giommoni E, Bergamo F, Milella M, Cavanna L, Di Marco M, et al.
ESMO Open
. 2023 Feb;
8(1):100777.
PMID: 36731325
Background: Information about the adherence to scientific societies guidelines in the 'real-world' therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative...
5.
Redegalli M, Schiavo Lena M, Cangi M, Smart C, Mori M, Fiorino C, et al.
Ann Surg Oncol
. 2022 Mar;
29(6):3492-3502.
PMID: 35230580
Background: Limited information is available on the relevant prognostic variables after surgery for patients with pancreatic ductal adenocarcinoma (PDAC) subjected to neoadjuvant chemotherapy (NACT). NACT is known to induce a...
6.
Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, et al.
ESMO Open
. 2021 Aug;
6(5):100238.
PMID: 34392104
Background: Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents. This study aimed at exploring safety profile, dose intensity, and activity of different...
7.
Tempero M, Oh D, Tabernero J, Reni M, Van Cutsem E, Hendifar A, et al.
Ann Oncol
. 2021 Feb;
32(5):600-608.
PMID: 33539945
Background: First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor microenvironment modulation. The safety and efficacy of first-line...
8.
Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco M, Rodriquenz M, et al.
ESMO Open
. 2021 Jan;
6(1):100032.
PMID: 33399070
Objective: Germline BRCA1-2 pathogenic variants (gBRCApv) increase the risk of pancreatic cancer and predict for response to platinating agents and poly(ADP-ribose) polymerase inhibitors. Data on worldwide gBRCApv incidence among pancreatic...
9.
Hammel P, Kindler H, Reni M, Van Cutsem E, Macarulla T, Hall M, et al.
Ann Oncol
. 2019 Sep;
30(12):1959-1968.
PMID: 31562758
Background: Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with...
10.
Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, et al.
J Bone Oncol
. 2018 Jul;
12:33-37.
PMID: 30042924
•Natural history of biliary cancers metastatic to bone•The role of skeletal events in patients with biliary cancer•Biliary cancer and bone metastases: role of bisphosphonates.